Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Boehringer Ingelheim
McKinsey
Merck
Colorcon

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

CLOBETASOL PROPIONATE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Clobetasol Propionate, and what generic alternatives are available?

Clobetasol Propionate is a drug marketed by Glenmark Pharms Ltd, Ingenus Pharms Llc, Perrigo Israel, Perrigo Uk Finco, Taro, Acp Nimble, Amneal Pharms Llc, Fougera Pharms Inc, Glenmark Pharms, Lupin Ltd, Mylan, Rising, Teligent Pharma Inc, Teva Pharms Usa, Xiromed, Zydus Pharms, Fougera Pharms, Perrigo Co, Actavis Mid Atlantic, Hi Tech, Aleor Dermaceuticals, Novel Labs Inc, Macleods Pharms Ltd, Saptalis Pharms, Tolmar, Wockhardt Bio Ag, Akorn, Apotex Inc, Paddock Llc, and Novast Labs. and is included in sixty-five NDAs.

The generic ingredient in CLOBETASOL PROPIONATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

Drug patent expirations by year for CLOBETASOL PROPIONATE
Drug Prices for CLOBETASOL PROPIONATE

See drug prices for CLOBETASOL PROPIONATE

Drug Sales Revenue Trends for CLOBETASOL PROPIONATE

See drug sales revenues for CLOBETASOL PROPIONATE

Recent Clinical Trials for CLOBETASOL PROPIONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Association pour la Recherche Clinique et ImmunologiqueN/A
Beni-Suef UniversityPhase 1
DermtreatPhase 2

See all CLOBETASOL PROPIONATE clinical trials

Recent Litigation for CLOBETASOL PROPIONATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Galderma Laboratories LP v. Akorn Inc2016-04-14
Delcor Asset Corporation v. Taro Pharmaceutical Industries, Ltd.2016-03-01
Galderma Laboratories LP v. Teligent Inc2015-12-04

See all CLOBETASOL PROPIONATE litigation

Pharmacology for CLOBETASOL PROPIONATE
Medical Subject Heading (MeSH) Categories for CLOBETASOL PROPIONATE
Synonyms for CLOBETASOL PROPIONATE
(11b,16b)-21-Chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
[(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
122C467
21-chloro-9-fluoro-11 beta-hydroxy-16 beta-methylpregna-1,4-diene-3,20-dione 17-propionate
21-Chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione (11beta,16beta)-
21-Chloro-9-fluoro-11b,17-dihydroxy-16b-methylpregna-1,4-diene-3,20-dione 17-propionate
21-chloro-9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate
21-Chloro-9-fluoro-11beta-hydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate
21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate
21-Chloro-9alpha-fluoro-11beta,17alpha-dihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17-Propionate
25122-46-7
779619577M
AB00383081_11
AB00383081-10
AB1009262
AC-17990
AC1L1OG9
AC1Q3T8C
AKOS015951278
AMOT0927
AN-14318
AS-12555
BCP04125
BCP0726000094
BCP9000539
BDBM39347
BRD-K10799896-001-10-6
BRD-K10799896-001-26-2
Butavate
C-22667
C25H32ClFO5
CAS-25122-46-7
CC-25914
CCG-220781
CCI 4725
CCI-4725
CGP 9555
CGP9555 pound>> CCl 4725 pound>>CGP 9555 pound>> CCl4725 pound>>CGP-9555 pound>> CCl-4725
CHEBI:31414
CHEMBL1159650
cid_32798
Clarelux
Clobesol
Clobestasol propionate
clobetasol 17-propanoate
Clobetasol 17-propionate
Clobetasol for peak identification, European Pharmacopoeia (EP) Reference Standard
CLOBETASOL PROPIONATE (EMOLLIENT)
Clobetasol propionate (JP17/USP)
Clobetasol propionate [USAN:JAN]
Clobetasol propionate [USAN:USP:JAN]
Clobetasol propionate E
Clobetasol propionate gel
Clobetasol propionate, analytical standard
Clobetasol propionate, European Pharmacopoeia (EP) Reference Standard
Clobetasol Propionate, Pharmaceutical Secondary Standard; Certified Reference Material
Clobetasol propionate, United States Pharmacopeia (USP) Reference Standard
Clobetasole propionate
Clobetasolpropionat mikron.
Clobetasolpropionate
Clobex
Cormax
Cormax (TN)
CPD000058745
CS-2594
D01272
DB01013
Dermoval
Dermovate
Dermoxinale
DSSTox_CID_25907
DSSTox_GSID_45907
DSSTox_RID_81219
DTXSID6045907
EBD6220
EINECS 246-634-3
Embeline
Embeline E
GR 2/925
GTPL7062
HMS2090A04
HMS2230H08
HMS3259A10
HMS3714M04
HY-13600
Impoyz
LS-118433
MFCD00058499
MLS000028708
MLS001076345
NC00551
NCGC00023373-03
NCGC00023373-04
NCGC00095078-01
Olux
Olux E
OLUX FOAM
Olux-E
Opera_ID_1470
Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-beta,17-dihydroxy-16-beta-methyl-, 17-propionate
Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-beta,17-dihydroxy-16-beta-methyl-,17-propionate
Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (11beta,16beta)-
Propionic acid clobetasol
s2584
SCHEMBL3997
SMR000058745
SR-01000000280
SR-01000000280-4
Temovate
Temovate E
Tox21_111414
Tox21_111414_1
UNII-779619577M
Yugofin
ZINC3977767
Paragraph IV (Patent) Challenges for CLOBETASOL PROPIONATE
Tradename Dosage Ingredient NDA Submissiondate
OLUX E AEROSOL, FOAM;TOPICAL clobetasol propionate 022013 2010-02-25
CLOBEX SPRAY;TOPICAL clobetasol propionate 021835 2008-09-29
CLOBEX SHAMPOO;TOPICAL clobetasol propionate 021644 2008-01-09
CLOBEX LOTION;TOPICAL clobetasol propionate 021535 2006-03-27
OLUX AEROSOL, FOAM;TOPICAL clobetasol propionate 021142 2005-06-27

US Patents and Regulatory Information for CLOBETASOL PROPIONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Mid Atlantic CLOBETASOL PROPIONATE clobetasol propionate SHAMPOO;TOPICAL 078854-001 Jun 7, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal Pharms Llc CLOBETASOL PROPIONATE clobetasol propionate OINTMENT;TOPICAL 210551-001 Aug 21, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Saptalis Pharms CLOBETASOL PROPIONATE clobetasol propionate SOLUTION;TOPICAL 211494-001 Oct 2, 2019 AT RX No No   Start Trial   Start Trial   Start Trial
Taro CLOBETASOL PROPIONATE clobetasol propionate SPRAY;TOPICAL 208842-001 Mar 26, 2018 AT RX No No   Start Trial   Start Trial   Start Trial
Fougera Pharms CLOBETASOL PROPIONATE clobetasol propionate SOLUTION;TOPICAL 075391-001 Feb 8, 1999 AT RX No No   Start Trial   Start Trial   Start Trial
Taro CLOBETASOL PROPIONATE clobetasol propionate SOLUTION;TOPICAL 075224-001 Nov 16, 1998 AT RX No No   Start Trial   Start Trial   Start Trial
Aleor Dermaceuticals CLOBETASOL PROPIONATE clobetasol propionate SPRAY;TOPICAL 211191-001 Oct 2, 2019 AT RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Harvard Business School
AstraZeneca
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.